Metabolon Target
Cannabinoids Targeted Panel
Measures 31 metabolites
Identify biomarkers
Improve sensitivity
Decipher impact
About Cannabinoids & Cannabinoid Metabolism
Endocannabinoids are endogenous lipid-based neurotransmitters that bind to cannabinoid receptors (CBRs). Endocannabinoids are naturally produced by the human body. They have been shown to regulate a wide range of physiological and cognitive processes, including fertility, pregnancy, pre-and postnatal development, motor control, appetite, food intake, pain sensation, mood, memory acquisition, and learning. In humans, exercise has been shown to increase endocannabinoid levels in plasma, mainly because endocannabinoids can effectively cross the blood-brain barrier (BBB) and contribute to exercise-induced euphoria in humans. Disorders of the endocannabinoid system have been related to several neuro-inflammatory diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and multiple sclerosis. Thus, a better understanding of the endocannabinoid system in humans is an essential step toward more sophisticated exploitation of this system to improve human health further.
The quantification of endocannabinoids has been challenging due to their low abundance and structural variability. Metabolon’s targeted metabolomics enables simultaneous absolute quantification of multiple cannabinoids. The results can be used for investigating the relative changes in metabolite concentrations and potential biomarker discovery. Metabolon offers you confidence in the routine quantification of cannabinoids for your research.
The Metabolon Cannabinoids Targeted Panel measures 31 cannabinoids. The sample preparation is customized to enrich these cannabinoids, and related metabolites for much better detection than most other methods can provide. Our validated method of cannabinoid detection and identification in human plasma samples can help you gain insight into the therapeutic potential of cannabinoids in key disease states such as chronic pain and neuro-inflammatory disease. Absolute quantification of these 31 cannabinoid metabolites provides deeper insights and detects known bioactive mediators of inflammation to enable you to gain insights into the metabolic consequences of these compounds.
Cannabinoids Targeted Panel Details
| LLOQ* | |
|---|---|
| Metabolite | Plasma (ng/mL) |
| Endocannabinoids and related molecules | |
| 2-Arachidonoyl Glycerol (2-AG) | 0.842 |
| 2-Arachidonyl Glycerol ether (2-AG Ether) | 1.77 |
| Arachidonoyl Ethanolamide (AEA) | 0.0946 |
| Arachidonoyl Glycine (NAGly) | 0.0946 |
| Arachidonoyl Serotonin (AA-5HT) | 0.0946 |
| Dihomo-γ-Linolenoyl Ethanolamide (DLEA) | 0.0946 |
| Docosatetraenoyl Ethanolamide (DEA) | 0.0946 |
| N-Arachidonoyl Dopamine (NADA) | 0.189 |
| N-Oleoyl Dopamine (ODA) | 0.189 |
| N-Palmitoyl Dopamine (PDA) | 0.142 |
| Linoleoyl Ethanolamide (LEA) | 0.0709 |
| Phytocannabinoids | |
| (-)-Δ8-Tetrahydrocannabinol (Δ8-THC) | 0.0946 |
| (±)-Δ9-Tetrahydrocannabinol (Δ9-THC) | 0.189 |
| Cannabichromene (CBC) | 0.189 |
| Cannabidiol (CBD) | 0.0946 |
| Cannabidiolic acid (CBDA) | 0.0946 |
| Cannabidivarin (CBDV) | 0.189 |
| Cannabidivarinic Acid (CBDVA) | 0.0946 |
| Cannabigerol (CBG) | 0.0946 |
| Cannabigerolic acid (CBGA) | 1.77 |
| Cannabinol (CBN) | 0.0946 |
| Δ9-Tetrahydrocannabinolic acid A (THCA-A) | 0.0946 |
| Abnormal Cannabidiol (Abn-CBD) | 0.0946 |
| Hexocannabitriol | 0.0946 |
| Tetrahydrocannabivarin (THCV) | 0.0946 |
| Cannabivarin (CBV) | 0.0946 |
| Human Metabolites of Phytocannabinoids | |
| (±)-11-Hydroxy-Δ9-THC (11-OH-THC) | 0.0946 |
| (±)-11-nor-9-Carboxy-Δ9- THC (11-COOH-THC) | 0.0946 |
| 7-Carboxy cannabidiol (7-COOH- CBD) | 0.0946 |
| 7-Hydroxy cannabidiol (7-OH-CBD) | 0.0946 |
| (−)-6α-hydroxy Cannabidiol (6α-OH-CBD) | 0.189 |
*Lower Limit of Quantitation (LLOQ) varies for each sample type.
Analysis Method and Instrumentation
LC-MS/MS (Agilent 1290 UHPLC/Sciex QTrap 5500 and 6500+)
| Sample Type and Required Amounts | |
|---|---|
| Sample Type | Sample Requirements |
| Plasma / serum | ≥ 300 µL |
Others on request
Disclaimer: This panel is for Research Use Only and is not to be used for diagnostic purposes.
Delivering Absolute Quantification for Research and Biomarker Analysis
Our readily available or custom developed quantitative assays help you achieve your research and biomarker validation objectives with precise and fully validated methods. Our targeted assays and panels cover >1,000 metabolites and lipids across a wide range of biochemical classes, metabolic pathways, and physiological processes, and they can be customized to best fit any application.
Applications for the Cannabinoids Targeted Panel
Inflammation
The importance of inflammation in the development of multiple diseases- and health-related conditions including neurodegeneration, diabetes, cardiovascular disease, cancer, and inflammatory bowel disease is undisputed. Metabolomics can inform on inflammatory processes by providing a readout of the small molecules of an organism, tissue, biofluid, etc. This allows for direct molecular phenotyping of inflammation beyond the standard protein markers of typical assays. Metabolon offers several targeted assays, including oxysterols, fatty acids, kynurenine/tryptophan, and a range of others (central carbon, glucose tolerance, branched-chain amino acids, β-hydroxybutyrate) that can also inform on overall cardiovascular health that is often linked with inflammatory processes.
Neuroscience
Big Insights with Metabolon
Cited in over 3,000 publications, we help scientists and manufacturers gain greater insight into their studies through metabolomics. See how our approach can become a successful part of your workflow.
Related Metabolomics Resources
Contact Us
Talk with an expert
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.
Corporate Headquarters
617 Davis Drive, Suite 100
Morrisville, NC 27560
